Lyme Disease & Tick-Borne Illness: Functional Medicine Treatment Guide

Quick answer: Lyme disease is the most common vector-borne illness in North America, with the CDC estimating 476,000 new diagnoses annually — yet standard two-tiered serology (ELISA + Western blot) misses approximately 30–50% of early infections and fails entirely in seronegative presentations. Post-treatment Lyme disease syndrome (PTLDS) affects 10–20% of treated patients and shares overlapping mechanisms with fibromyalgia, ME/CFS, and autoimmune conditions. Functional medicine approaches PTLDS through immune modulation, mitochondrial restoration, gut microbiome repair, and targeted co-infection management — addressing the multi-system dysfunction that persists when standard antibiotics clear Borrelia but fail to resolve the immunological aftermath.

The Lyme Disease Epidemic: Scale, Geography, and Underdiagnosis

Lyme disease, caused by Borrelia burgdorferi sensu lato spirochetes transmitted by Ixodes ticks, was officially recognized as a distinct illness in 1977 following an outbreak in Lyme, Connecticut. Today it represents a public health crisis of far greater scope than official reporting reflects. The CDC’s most recent estimates suggest approximately 476,000 Americans are diagnosed and treated annually — a figure 10-fold higher than passive surveillance data, reflecting the now-acknowledged massive underdiagnosis burden.

Geographic distribution has expanded significantly beyond traditional New England and upper Midwest foci. Ixodes scapularis (black-legged tick) range has expanded northward by over 320 km since the 1990s driven by climate change and deer population expansion. Ixodes pacificus on the West Coast and Ixodes ricinus throughout Europe and Asia carry regionally distinct Borrelia species with partially different clinical manifestations. Travel-associated Lyme disease further distributes cases beyond endemic regions.

The clinical challenge is compounded by the nonspecific early presentation: flu-like illness with fatigue, myalgia, headache, and arthralgia occurs in many early Lyme cases, and the pathognomonic erythema migrans (EM) rash — present in approximately 70-80% of cases when carefully documented — is often missed, misidentified as a spider bite, or absent entirely. Disseminated Lyme — affecting the nervous system (neuroborreliosis), heart (Lyme carditis with AV block), and joints (Lyme arthritis) — develops when early infection goes unrecognized and untreated.

Why Standard Lyme Testing Fails: The Serology Problem

The CDC/IDSA two-tiered testing algorithm — ELISA screening followed by Western blot confirmation — was designed to optimize specificity (minimize false positives) rather than sensitivity, creating significant clinical consequences in early infection and certain patient populations.

The Early Infection Window Problem

IgM antibodies typically appear 2-4 weeks after infection; IgG antibodies require 4-8 weeks to develop. In the critical first 2-4 weeks when treatment is most effective, serological testing is frequently negative despite active infection. The CDC’s own guidance acknowledges this limitation and recommends treating clinical erythema migrans empirically regardless of serology — yet many clinicians still insist on positive testing before prescribing antibiotics, creating dangerous delays.

Cook 2019 (PLOS ONE) reviewed 207 Lyme disease cases confirmed by clinical criteria, finding only 59% had positive two-tiered serology at initial presentation. Multiple studies demonstrate sensitivity of 29-50% in the first two weeks of infection. This performance gap in early disease — when treatment is most effective and complications most preventable — represents a fundamental limitation of current standard testing protocols.

Seronegative Lyme Disease

A subset of patients with clinical presentations consistent with Lyme disease and documented tick exposure never develop detectable antibody responses. Proposed mechanisms include: early antibiotic treatment truncating the antibody response before it reaches detectable thresholds; immune evasion mechanisms in Borrelia burgdorferi including phase variation and downregulation of immunogenic surface proteins; and individual host immune variation affecting antibody kinetics. The existence of seronegative Lyme disease remains contested in mainstream medicine but is clinically encountered and supported by case literature.

Emerging Testing Approaches

Several alternative testing modalities offer potential advantages over standard serology. Direct detection approaches — PCR for Borrelia DNA in blood, urine, or synovial fluid — provide pathogen-specific evidence independent of antibody response, though sensitivity is limited by the low spirochete burden in blood during most disease stages. Next-generation sequencing approaches capable of detecting Borrelia DNA directly from clinical samples represent a genuine advance that may substantially improve early sensitivity over the next decade.

CD57+ NK cell count testing — measuring a natural killer cell subset frequently depressed in chronic Lyme — is used by some practitioners as an immune function marker, though its specificity for Borrelia infection versus other causes of immunosuppression remains uncertain. The Tick-Borne Disease Working Group (established by the 21st Century Cures Act) has recommended federal investment in improved diagnostic testing to address the acknowledged gaps in current serology performance.

Co-Infections: The Multi-Pathogen Reality of Tick Bites

Ixodes ticks in endemic areas commonly carry multiple pathogens simultaneously, and a significant proportion of Lyme-endemic tick bites transmit co-infections that profoundly alter clinical presentation, treatment response, and chronicity. Ignoring co-infections is perhaps the most consequential error in Lyme disease management.

Babesia: The Intraerythrocytic Parasite

Babesia microti is the most common Lyme co-infection in northeastern North America, with co-infection rates of 2-12% in confirmed Lyme patients in endemic areas and up to 40% in some high-endemicity communities. As an intraerythrocytic protozoan parasite — structurally analogous to malaria — Babesia is completely unresponsive to doxycycline and amoxicillin, the standard Lyme antibiotics. Untreated Babesia co-infection is associated with more severe Lyme disease, relapsing fevers, hemolytic anemia, night sweats, and significantly worse PTLDS outcomes.

Standard treatment is atovaquone plus azithromycin (7-10 days for mild-moderate disease; 6+ weeks for severe or immunocompromised cases). The clinical pearl: patients who complete standard Lyme treatment but fail to improve — particularly those with hemolytic anemia, extreme fatigue disproportionate to other symptoms, or night sweats — should be evaluated for concurrent Babesia through blood smear, Babesia PCR, and Babesia microti IgM/IgG serology.

Bartonella: The Stealth Co-Infection

Bartonella species (B. henselae, B. quintana, B. vinsonii) are intracellular bacteria transmitted by ticks, fleas, lice, and sand flies that infect endothelial cells, erythrocytes, and macrophages, creating a persistent intracellular infection that evades conventional antibiotics. Bartonella’s clinical presentation is protean: neuropsychiatric symptoms (anxiety, rage, brain fog, peripheral neuropathy), skin manifestations (striae-like lesions, nodular angiomas), GI symptoms, lymphadenopathy, and fatigue are all documented.

Testing for Bartonella is notoriously unreliable. Standard Bartonella IgM/IgG serology has poor sensitivity for tick-borne species. Galaxy Diagnostics’ digital droplet PCR and fluorescent in-situ hybridization (FISH) assays have higher sensitivity for Bartonella DNA in blood. Emerging research has identified Bartonella in patients with neuropsychiatric conditions previously attributed to primary psychiatric illness — a finding with profound implications for patients misdiagnosed with treatment-resistant anxiety or depression who have undiagnosed tick-borne illness.

Ehrlichia and Anaplasmosis: The Obligate Intracellular Bacteria

Human monocytic ehrlichiosis (HME, caused by Ehrlichia chaffeensis) and human granulocytic anaplasmosis (HGA, caused by Anaplasma phagocytophilum) are Ixodes-transmitted co-infections causing acute febrile illness with leukopenia, thrombocytopenia, elevated liver enzymes, and severe systemic inflammation. Both respond well to doxycycline, making their identification important primarily because they explain clinical severity and guide treatment adequacy. Blood smear evaluation (morulae in neutrophils for Anaplasma, in monocytes for Ehrlichia) provides rapid presumptive diagnosis; PCR confirms.

HGA has an estimated case fatality rate of 0.5-1% in treated patients and higher in untreated or immunocompromised individuals. Severe presentations include acute respiratory distress syndrome, renal failure, and opportunistic infections from the profound immunosuppression these organisms cause. Early recognition and appropriate antibiotic therapy are essential for preventing severe outcomes.

Borrelia Pathogenesis: Why Lyme Disease Is So Hard to Eradicate

Understanding why Borrelia burgdorferi causes chronic, treatment-resistant illness requires examining its unique biological adaptations — among the most sophisticated host-evasion mechanisms of any pathogen.

Biofilm Formation and Antibiotic Tolerance

Borrelia burgdorferi forms biofilms — structured communities of bacteria encased in a self-produced extracellular matrix — both in vitro and in host tissues. Sapi 2012 (PLOS ONE) demonstrated Borrelia biofilm formation in human cortical brain tissue samples from Lyme patients, and multiple groups have documented biofilm in synovial tissue and other reservoirs. Biofilm bacteria exhibit dramatically increased antibiotic tolerance (100-1000x higher MIC compared to planktonic forms) through multiple mechanisms: reduced metabolic activity impairing antibiotic targets that require active replication; physical barrier of the biofilm matrix reducing antibiotic penetration; and upregulation of efflux pumps and stress-response genes.

The clinical implication is significant: standard antibiotic courses targeting planktonic Borrelia may not adequately penetrate and eradicate biofilm communities, potentially explaining treatment failures and the persistence of symptoms after standard therapy. Biofilm-disrupting agents (NAC, serrapeptase, lumbrokinase) are used adjunctively in functional medicine protocols. Combination antibiotic protocols — adding biofilm-active agents such as cefuroxime or disulfiram to standard regimens — are being explored in clinical practice, though robust RCT evidence is limited.

Persister Cells and Antibiotic Tolerance

Beyond biofilm, Borrelia demonstrates the capacity to enter metabolically dormant “persister” states that are antibiotic-tolerant without genetic resistance. Feng 2015 (Emerging Microbes and Infections) identified Borrelia persister cells surviving doxycycline treatment that could resume replication after antibiotic removal. In vitro high-throughput screening identified combinations including daptomycin plus doxycycline plus cefuroxime, and disulfiram (an FDA-approved alcohol deterrent), as having activity against Borrelia persisters not achieved by standard antibiotics alone.

Disulfiram as a Lyme treatment gained significant attention following case series documenting sustained improvement in treatment-refractory Lyme patients, followed by ongoing clinical research. While not FDA-approved for Lyme and not yet validated in controlled trials, the mechanistic rationale and preliminary clinical observations have established it as an active area of investigation in chronic Lyme medicine.

Immune Evasion and Molecular Mimicry

Borrelia employs multiple immune evasion strategies. Variable major protein-like sequence expressed (VlsE) — encoded on a linear plasmid — undergoes continuous antigenic variation during infection, producing a constantly shifting surface protein target that evades existing antibody responses. This variation is why the C6 VlsE-based ELISA test was developed, as C6 is a conserved peptide within VlsE that doesn’t vary between strains.

Molecular mimicry between Borrelia antigens and host proteins may contribute to autoimmune phenomena in chronic Lyme. Cross-reactivity between OspA (Borrelia outer surface protein A) and human lymphocyte antigens has been demonstrated, potentially explaining antibiotic-refractory Lyme arthritis as an autoimmune condition triggered by infection but maintained by cross-reactive T-cells — analogous to post-streptococcal rheumatic fever. This mechanism supports the use of anti-inflammatory and immune-modulating interventions alongside or following antibiotic therapy in selected patients.

Post-Treatment Lyme Disease Syndrome: Evidence, Mechanisms, and Functional Medicine Approaches

Post-Treatment Lyme Disease Syndrome (PTLDS) — defined as ongoing symptoms of fatigue, pain, cognitive dysfunction, and sleep disturbance persisting more than 6 months after standard antibiotic therapy in patients with documented prior Lyme disease — affects approximately 10-20% of treated Lyme patients. This translates to 50,000-100,000 new PTLDS cases annually in the US based on CDC incidence estimates.

The Evidence on Extended Antibiotic Therapy

Four randomized controlled trials have evaluated extended antibiotic therapy for PTLDS with mixed results. Klempner 2001 (NEJM) tested 90-day IV ceftriaxone followed by 60-day oral doxycycline versus placebo in PTLDS patients — no significant benefit was found, though the trial had significant methodological limitations including heterogeneous patient selection and limited power. Fallon 2008 (Neurology) studied 70-day IV ceftriaxone in neuropsychiatric PTLDS — demonstrating modest cognitive improvement at 12 weeks that was not sustained at 24 weeks, with significant adverse events in the treatment group.

Berende 2016 (NEJM) compared 12-week courses of doxycycline, hydroxychloroquine plus clarithromycin, or placebo in 281 PTLDS patients — no significant difference between treatment groups in health-related quality of life at 14 weeks, though the trial has been criticized for not adequately screening for co-infections and not using biofilm-active antibiotic combinations. The absence of definitive RCT evidence for extended antibiotics does not mean treatments have no effect — it means adequately powered, properly designed trials with better patient selection have not been conducted.

PTLDS Mechanisms Driving the Functional Medicine Protocol

Multiple overlapping mechanisms contribute to PTLDS, each representing a therapeutic target:

Neuroinflammation: Schutzer 2011 (PLOS ONE) demonstrated altered cerebrospinal fluid proteomics in PTLDS patients compared to healthy controls, with patterns overlapping ME/CFS — including complement activation, oxidative stress markers, and inflammatory mediator profiles. Inflammatory cytokine patterns (elevated IL-6, TNF-alpha, IL-17) persist in PTLDS despite antibiotic clearance. Bhatt 2022 demonstrated elevated TSPO — a marker of microglial activation — in PTLDS brain imaging using PET scanning, providing direct evidence of ongoing neuroinflammation after antibiotic therapy.

Autonomic Nervous System Dysfunction: Postural orthostatic tachycardia syndrome (POTS), inappropriate sinus tachycardia, and other dysautonomic features are common in PTLDS and contribute to exercise intolerance, brain fog, and fatigue. The vagus nerve — the primary anti-inflammatory circuit — is directly affected by neuroinflammation and Borrelia neurotoxins, impairing the cholinergic anti-inflammatory pathway and perpetuating the inflammatory cycle.

Mitochondrial Dysfunction: Bacterial toxins, reactive oxygen species generated during infection, and the mitochondrial-targeting effects of some antibiotics (particularly doxycycline, which shares its ribosome-inhibiting mechanism with mitochondrial ribosomes) all impair mitochondrial function. Reduced ATP production manifests as post-exertional malaise and cognitive dysfunction characteristic of PTLDS and ME/CFS.

Gut Microbiome Disruption: Multiple antibiotic courses — a common experience in chronic Lyme — profoundly alter gut microbiome composition. Broad-spectrum antibiotics reduce Lactobacillus, Bifidobacterium, and Bacteroides populations while potentially enriching Clostridium difficile and Candida albicans. Dysbiosis propagates systemic inflammation through increased intestinal permeability and lipopolysaccharide translocation — amplifying the neuroinflammation that drives PTLDS symptoms.

Mast Cell Activation Syndrome (MCAS): Borrelia antigens and the inflammatory milieu of tick-borne illness can trigger MCAS, characterized by episodic mediator release (histamine, tryptase, prostaglandins) causing flushing, GI symptoms, anaphylaxis-like reactions, and cognitive dysfunction. MCAS in the context of Lyme represents a distinct treatment target requiring H1/H2 antihistamines, mast cell stabilizers (cromolyn sodium, quercetin, luteolin), and low-histamine dietary support.

The Functional Medicine Protocol for Lyme Disease and PTLDS

A functional medicine approach to Lyme disease and PTLDS integrates the best available antimicrobial evidence with comprehensive assessment and correction of the multi-system dysfunctions that perpetuate chronic illness. This is not an alternative to appropriate antibiotic therapy — it is a complement to it, addressing the terrain in which bacterial infection occurs and the immunological aftermath that persists after pathogen clearance.

Step 1: Comprehensive Co-Infection Screening

No PTLDS protocol is valid without ruling out undertreated or unrecognized co-infections. Recommended co-infection panel: Babesia microti IgM/IgG plus Babesia PCR; Bartonella henselae IgM/IgG plus Bartonella digital droplet PCR (Galaxy Diagnostics); Ehrlichia chaffeensis IgM/IgG plus PCR; Anaplasma phagocytophilum IgM/IgG plus PCR; Rickettsia IgG; EBV/CMV reactivation panel (elevated EA-IgG with high EBNA suggests reactivation in immunocompromised host). CD57+ NK cell count (low values below 60 cells per microliter associated with chronic Lyme in multiple publications) and comprehensive complement C3/C4 assessment complete the immune function baseline.

Step 2: Neuroinflammation Reduction Protocol

Targeting the persistent neuroinflammation underlying brain fog, cognitive dysfunction, and pain amplification is central to PTLDS recovery:

Low-Dose Naltrexone (LDN) 1.5-4.5 mg nightly: By transiently blocking opioid receptors, LDN triggers compensatory upregulation of endogenous opioids and modulates microglial activation through TLR4 antagonism. Younger 2014 (PAIN) demonstrated significant fibromyalgia pain reduction with LDN; multiple studies demonstrate immune-modulating effects. In PTLDS, LDN’s mechanism directly addresses the documented neuroinflammation seen on PET imaging. Off-label use requires compounding pharmacy formulation.

Omega-3 Fatty Acids (EPA+DHA 3-4 g/day): DHA is the primary structural fatty acid of neuronal membranes; EPA is the primary anti-inflammatory omega-3 in brain tissue. Specialized pro-resolving mediators (SPMs) derived from EPA/DHA — including resolvins, protectins, and maresins — actively resolve neuroinflammation without immunosuppression. Optimal omega-3 index above 8% should be verified by testing before therapeutic dosing.

Palmitoylethanolamide (PEA) 600-1200 mg twice daily: An endogenous fatty acid amide that downregulates mast cell activation and neuroinflammation through PPAR-alpha agonism. Multiple clinical trials demonstrate PEA efficacy in chronic pain and neuroinflammatory conditions; its dual action on neuroinflammation and MCAS makes it particularly relevant in PTLDS.

Step 3: Mitochondrial Restoration

Post-exertional malaise and severe fatigue in PTLDS reflect impaired mitochondrial ATP production. A targeted mitochondrial support protocol addresses this mechanistically: CoQ10 ubiquinol 200-400 mg with food; D-Ribose 5 g three times daily (Teitelbaum 2012 demonstrated significant energy improvement in fibromyalgia/CFS patients); L-carnitine 2 g twice daily for fatty acid transport into mitochondria; B-complex with active cofactors (methylcobalamin, methylfolate, riboflavin, P5P); magnesium malate 400 mg; alpha-lipoic acid 600 mg as a mitochondrial antioxidant and cofactor for the pyruvate dehydrogenase complex.

Critically, graded exercise therapy (GET) as traditionally prescribed for ME/CFS-like conditions is contraindicated in PTLDS with post-exertional malaise. Current expert consensus recommends heart rate-guided activity management staying below the anaerobic threshold — typically below 60% maximum heart rate or below the point of symptom exacerbation — until mitochondrial function is restored. Forced exercise worsens post-exertional malaise and can cause significant setbacks in recovery.

Step 4: Gut Microbiome Restoration After Antibiotics

Aggressive microbiome rehabilitation after antibiotic courses is essential to preventing post-antibiotic dysbiosis from perpetuating systemic inflammation. During antibiotics: Saccharomyces boulardii 5 billion CFU daily (taken 2 hours apart from antibiotics, resistant to antibiotics). McFarland 1994 (JAMA) demonstrated 57% reduction in antibiotic-associated diarrhea with S. boulardii. Post-antibiotic: Multi-strain probiotic including Lactobacillus GG, L. rhamnosus, L. acidophilus, and Bifidobacterium longum at 50-100 billion CFU for minimum 8-12 weeks; targeted prebiotic fiber (inulin, arabinogalactan, PHGG); fermented foods (sauerkraut, kimchi, kefir if tolerated). Comprehensive microbiome testing at months 2-6 to identify persistent dysbiosis, SIBO, or fungal overgrowth requiring targeted treatment.

Step 5: Herbal Antimicrobial Support

Laboratory research has identified several botanical compounds with in vitro activity against Borrelia burgdorferi — including persister and stationary-phase forms. Feng 2020 (Antibiotics) screened 35 herbal extracts against stationary-phase Borrelia, identifying Japanese knotweed (Polygonum cuspidatum, containing resveratrol), cat’s claw (Uncaria tomentosa), Chinese skullcap (Scutellaria baicalensis), sweet wormwood (Artemisia annua), and cryptolepis (Cryptolepis sanguinolenta) as having the greatest in vitro activity — including against forms not killed by doxycycline alone. Resveratrol from Japanese knotweed also has documented anti-biofilm and anti-inflammatory properties independent of direct antimicrobial effects. These herbal antimicrobials are used clinically in antibiotic-refractory PTLDS under informed clinical supervision, recognizing that in vitro to clinical efficacy translation requires further validation.

Step 6: Mold/Biotoxin Assessment if PTLDS Stalls

Ritchie Shoemaker’s work on Chronic Inflammatory Response Syndrome (CIRS) has identified a genetically susceptible population (approximately 25% carry HLA-DR gene variants associated with impaired biotoxin clearance) who mount amplified inflammatory responses to mold, Lyme, cyanobacteria, and other biotoxins. In PTLDS patients who fail to improve with standard functional protocols, assessment for concurrent mold exposure and CIRS is clinically important. The Shoemaker panel includes: TGF-beta1 (elevated in CIRS), MSH/melanocyte-stimulating hormone (depleted, affecting pain, sleep, and immunity), MMP-9 (elevated), VEGF (dysregulated), and VIP/vasoactive intestinal polypeptide (depleted). Positive biotoxin findings suggest concurrent environmental illness requiring mold remediation and binder therapy alongside standard Lyme protocols.

Prevention: The Most Effective Lyme Strategy

Given the diagnostic challenges, treatment controversies, and risk of PTLDS, prevention remains the most cost-effective approach to Lyme disease. Evidence-based prevention includes: DEET 20-30% or picaridin-based repellents applied to skin; permethrin-treated clothing (remains effective through multiple washes and kills ticks on contact); light-colored clothing for tick detection; thorough tick checks within 2 hours of outdoor exposure; and showering promptly after outdoor exposure. Landscaping modifications — leaf removal, wood chip barriers at forest-lawn interfaces, deer fencing — reduce residential tick density significantly.

Prophylactic doxycycline: A single 200 mg dose administered within 72 hours of a deer tick bite attached for 36 or more hours reduced Lyme transmission by 87% in the Nadelman 2001 NEJM trial — making it the most evidence-based preventive intervention in high-risk tick exposure scenarios. The 72-hour window and minimum attachment duration criteria should guide clinical decision-making.

The Pfizer/VLA-Biologicals Lyme vaccine (VLA15) completed successful Phase 3 VALOR trial enrollment demonstrating 79-89% efficacy against laboratory-confirmed Lyme disease. FDA review and ACIP guidance are anticipated to potentially make this vaccine available for high-risk individuals in endemic areas — representing a significant public health advance that could substantially reduce the Lyme disease burden in the northeastern and upper Midwestern United States.

If you are experiencing symptoms suggestive of Lyme disease, have been diagnosed with Lyme disease and are struggling with persistent symptoms, or want comprehensive evaluation for tick-borne co-infections and functional approaches to recovery, call our office at (810) 206-1402 to schedule a consultation. Functional medicine offers the most comprehensive framework for evaluating and treating the multi-system complexity of Lyme disease and PTLDS.

Frequently Asked Questions

How long does Lyme disease take to treat?

Standard IDSA guidelines recommend 14-21 days of doxycycline for uncomplicated early Lyme disease, 14-21 days for early disseminated disease with cardiac manifestations, and 28 days for Lyme arthritis or late neurological disease. Early treatment is the most effective; appropriately treated early Lyme resolves completely in the majority of patients. PTLDS — which affects 10-20% of treated patients — is a distinct post-infectious syndrome that may require months of functional medicine support regardless of antibiotic course duration.

Can Lyme disease cause psychiatric symptoms?

Yes. Neuropsychiatric Lyme (Lyme encephalopathy) is a well-documented manifestation of disseminated Borrelia infection involving cognitive dysfunction, depression, anxiety, rage, obsessive-compulsive behaviors, and personality changes. Bartonella co-infection is particularly associated with neuropsychiatric symptoms including severe anxiety, intrusive thoughts, and treatment-resistant depression. Patients with new-onset or significantly worsening psychiatric symptoms in tick-endemic regions or with outdoor exposure history warrant evaluation for tick-borne illness including comprehensive serology and co-infection testing.

Is chronic Lyme disease real?

“Chronic Lyme disease” is a contested term encompassing several distinct patient populations: true PTLDS with documented prior infection, undiagnosed or undertreated Lyme, seronegative Lyme, and overlapping conditions misattributed to Lyme. The symptom burden in PTLDS is real, measurable, and associated with documented neuroinflammation on PET imaging, immune dysfunction, and mitochondrial impairment — regardless of whether active Borrelia replication is occurring. The treatment controversy should not prevent compassionate, evidence-based functional medicine evaluation of individual patients.

What supplements help with Lyme disease recovery?

The functional medicine approach prioritizes supplements targeting documented mechanisms in PTLDS: CoQ10 ubiquinol (200-400 mg) and D-Ribose (5 g three times daily) for mitochondrial support; omega-3 fatty acids EPA plus DHA (3-4 g daily) for neuroinflammation resolution; low-dose naltrexone (1.5-4.5 mg nightly, prescription required) for microglial modulation; palmitoylethanolamide (PEA, 600 mg twice daily) for mast cell stabilization and neuroinflammation; Saccharomyces boulardii during antibiotic courses for gut protection; and multi-strain probiotics (50-100 billion CFU) for microbiome restoration. Herbal antimicrobials (Japanese knotweed, cat’s claw, cryptolepis) show preliminary evidence for Borrelia persister activity and are used clinically in refractory PTLDS under medical supervision.

Lyme Disease & PTLDS: Co-Infections, Babesia, Bartonella, and Neuroinflammation